BOSTON, Massachusetts, May 2026
Kernal Biologics announced it will present new data on its mRNA 2.0 platform and T-cell-targeted lipid nanoparticle (tLNP) technology at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, highlighting a breakthrough approach to in vivo CAR-T cell programming. The company’s platform integrates AI-driven mRNA design with targeted delivery systems, enabling highly selective activation of therapeutic payloads directly inside the body. This innovation addresses key limitations of traditional CAR-T therapies, including complex manufacturing, high cost, and limited accessibility, positioning Kernal Biologics at the forefront of next-generation cell and gene therapy innovation.
AI-Driven mRNA Design Enables Precision Targeting
A central component of Kernal Biologics’ platform is its machine learning-based mRNA engineering pipeline, which enables precise control over where and when therapeutic proteins are expressed. The company reported up to 40-fold cell-selective translation in vitro and 10-fold oncoselectivity in vivo, demonstrating a significant leap in target specificity and safety.
By incorporating selective translation mechanisms, the platform ensures that therapeutic activity occurs only within intended target cells, reducing off-target effects and improving clinical outcomes. This dual-layered approach—combining targeted delivery with controlled gene expression—represents a major advancement in precision medicine and RNA therapeutics, particularly in oncology and immune-related diseases.
Targeted LNP Technology Enables In Situ CAR-T Programming
Advertisement
Kernal Biologics also showcased its proprietary T-cell-targeted LNPs (tLNPs), designed to deliver mRNA payloads directly to resting and activated T cells in vivo. Unlike conventional CAR-T therapies that require ex vivo cell extraction and modification, this approach enables in situ programming of T cells through a simple intravenous infusion, dramatically simplifying treatment logistics.
Preclinical data demonstrated rapid and selective T-cell transduction, with successful redirection away from the liver and fast peripheral B-cell depletion within days in mouse models. This capability has the potential to transform CAR-T therapy into a scalable, off-the-shelf treatment, making advanced immunotherapies accessible to a broader patient population across standard healthcare settings.
Advancing the Future of Scalable Cell Therapies
The platform’s “checks-and-balances” system—combining targeted LNP delivery and selective mRNA translation—addresses critical challenges in safety and efficacy that have historically limited in vivo gene and cell therapies. By enabling precise control over therapeutic activation, Kernal Biologics is advancing toward a future where cell therapies can be administered at any hospital without complex infrastructure. This approach also reduces toxicity risks and manufacturing constraints, which are major barriers to widespread adoption of CAR-T treatments.
The company’s presentations at ASGCT 2026 underscore a broader shift toward AI-enabled, in vivo therapeutic programming, where cells can be engineered directly داخل the human body to fight disease. With strong preclinical data and a scalable platform, Kernal Biologics is positioning itself as a key innovator in the evolution of RNA-based and cell-based therapies, particularly for blood cancers and autoimmune diseases.
This advancement highlights the convergence of artificial intelligence, mRNA technology, and targeted delivery systems, driving a new era of precision oncology and immunotherapy. By overcoming traditional limitations of CAR-T therapies, Kernal Biologics is paving the way for faster, safer, and more accessible next-generation treatments.
Source: Kernal Biologics press release
